Brind.
  1. FDA approved UroGen Pharma Ltd.'s second product for bladder cancer, which the company has operations in Israel.

FDA approved ZUSDURI, an innovative formulation of mitomycin, for bladder cancer.

2 reports, 1 independent Updated 00:00
Still developing
Reports
2
Developments
2
Repetition
0%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

FDA approved ZUSDURI, an innovative formulation of mitomycin, for bladder cancer.

Who's involved

What this event is mainly about
FDA

How it developed

Newest first. Tap a step to see who reported it.
  1. ZUSDURI reported $68M revenue and FDA accepted NDA for UGN-103.1 source
  2. FDA approved ZUSDURI for bladder cancer, marking a major milestone for UroGen Pharma.

Keep exploring

Part of

FDA approved UroGen Pharma Ltd.'s second product for bladder cancer, which the company has operations in Israel. All 1 developments

The entities involved

Coverage

Newest first; wire copies grouped